News

A new long-read approach solves an old genetic mystery

Researchers pioneered a new strategy for diagnosing puzzling genetic diseases, expanding scientists’ capability to study their causes and pathophysiology.
Written byMaggie Chen
| 5 min read
Mutations that are structural variants, or that are located in non-coding regions of the genome, are often difficult to detect.

Mutations that are structural variants, or that are located in non-coding regions of the genome, are often difficult to detect.

Creative Commons

For many years, a curious and seemingly invisible mystery existed within a Dutch family. Several members of the family developed choroideremia, a rare form of progressive retinal degeneration that ultimately causes severe vision loss or blindness. Doctors knew that family members passed down choroideremia to their offspring, but couldn’t figure out what exactly caused the disease. Where did the answer lie within the epically complex tangle of the human genome?

Under the guidance of geneticists Susanne Roosing and Alexander Hoischen at Radboud University Medical Center, scientists leveraged multiple long-read methods to finally find the causative variant for choroideremia in this family (1). Rather than depending on the more commonly used methods of whole exome or whole genome sequencing, the researchers combined optical genome mapping with long-read whole genome sequencing to discover what went wrong in the DNA.

Choroideremia is usually linked to pathogenic variants in the CHM gene (named for choroideremia), and clinical diagnoses of choroideremia can be traced back to mutations in the CHM gene for more than 90% of cases (2). In the Dutch family, however, there was no traceable variant in the CHM gene’s DNA.

“It’s not really clear what the etiology of the disease is. We understand what the pathology looks like, and we understand that it’s an X-linked disease,” said Maureen McCall, an ophthalmology researcher at the University of Louisville who was unaffiliated with the study. “We don’t always understand where the defect arises and how that defect translates into vision loss.”

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

  • Maggie Chen Headshot

    Maggie is a scientist and science journalist covering health, biology, and bioengineering. She graduated from Harvard College in 2022 with a degree in developmental biology and the history of science. Her writing has appeared in the New York Times, WIRED, Massive Science, and Lady Science. She enjoys watching heart cells beat under a microscope, designing children’s books, and making brunch.

    View Full Profile

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Crystal Girod, Senior Product Manager at Beckman Coulter Life Sciences, featured in a “Tell Us What You Know” graphic titled “Making Lab Automation More Accessible,” alongside the Beckman Coulter Life Sciences logo.
Explore how advances in liquid handling are making automation more accessible, flexible, and practical for modern labs.
Puzzle pieces spelling “DATA” alongside connected icons representing data analysis, storage, and reporting.
Earlier insight into analytical data can help laboratories recognize emerging trends and maintain method performance over time.
3D illustration of an antibody-drug conjugate with cytotoxic payloads attached to an antibody.
Explore how integrated cell-based assays reveal the mechanisms that drive antibody-drug conjugate activity and inform candidate selection.